78 Views | 25 Downloads
Pinar Gumus Balikcioglu, Email: pinar.gumus@duke.edu
CJ, JB, MM and OI performed metabolomics and biochemical analysis and interpretation of the metabolomics data. CJ was responsible for writing the manuscript. MB performed advanced statistical analysis; TO and SG consulted on advanced statistical analysis. SA contributed to data collection and database generation. PJW, TO and SG contributed to interpretation of the data and critically reviewed the manuscript. MF was responsible for development of the research question, conception and design of the research project, interpretation of the data and writing of the manuscript. PGB was responsible for development of the research question, conception and design of the research project, obtaining funding, acquisition of data, statistical analysis and interpretation of the data, and writing the manuscript.
We would like to thank our patients and their families, Emory University School of Medicine Discovery Program, Duke Office of Clinical Research, Children’s Clinical Research Unit, Duke Clinical Research Training Program, The Metabolomics Core Laboratory at the Stedman Center/Duke Molecular Physiology Institute, Division of Pediatric Endocrinology, Duke Healthy Life Styles Program, Primary Care Clinics, and Center for Childhood Obesity Research. We would like to thank Huaxia Cui for her technical assistance with immunoassays and conventional metabolites measurements. We also would like to thank Dr. Christopher Newgard for his help with interpretation of the data.
CJT, MB, JB, MM, OI, SA, TØ and PGB have no conflicts of interest to declare. Dr Grambow reports receiving consulting fees from Gilead Sciences for serving on multiple data monitoring committees. MF is a co‐investigator on a grant from the American Heart Association that deals with the pathogenesis and treatment of childhood obesity. MF is also the local PI on a Rhythm‐sponsored study of identification and treatment of children and adults with monogenic obesity, and member of a Data Safety Monitoring Board for a separate Rhythm‐sponsored study of treatment of patients with syndromic obesity. PJW reports a pending patent for metabolic biomarkers of NAFLD/NASH and related disease phenotypes and a pending patent for compositions and methods for treating NAFLD/NASH and related disease phenotypes.
P.G.B. was supported by Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under award number K12 HD043494‐14, NIDDK under the award number K23DK117067, Children's Miracle Network Hospitals partnerships and programmes benefiting Duke Children's, Derfner Foundation Research Grant, and Duke University Pediatric Departmental Support, Duke Strong Start Award Program and Duke Private Diagnostic Clinic Enhanced Academics in a Basic Laboratory Environment (ENABLE) career development programme. PJW is supported by A Pathways to Stop Diabetes Award #1‐16‐INI‐17 from the American Diabetes Association. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other support resources.
© 2021 The Authors. Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd